RESEARCHER PROFILE

David L. Rimm

← Back to Yale University

D

Yale University

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment StudiesCutaneous Melanoma Detection and ManagementAI in cancer detectionHead and Neck Cancer Studies

David L. Rimm works in Cancer Immunotherapy and Biomarkers, Breast Cancer Treatment Studies, Cutaneous Melanoma Detection and Management, AI in cancer detection, Head and Neck Cancer Studies. Recorded institutional associations include Yale University.

1,486Publications
70,716Citations
134H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. X-Tile

    2004 · 3,744 citations
  2. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    2014 · 3,113 citations
  3. Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology

    2019 · 1,685 citations
  4. PD-L1 as a biomarker of response to immune-checkpoint inhibitors

    2021 · 1,558 citations
  5. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

    2020 · 1,553 citations
  6. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

    2005 · 1,549 citations
  7. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

    2009 · 1,412 citations
  8. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the αEβ7 integrin

    1994 · 1,177 citations
  9. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

    2015 · 837 citations
  10. Validation of Tissue Microarray Technology in Breast Carcinoma

    2000 · 799 citations
  11. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

    2017 · 799 citations
  12. Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis

    2006 · 796 citations
  13. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

    2017 · 782 citations
  14. Automated subcellular localization and quantification of protein expression in tissue microarrays

    2002 · 764 citations
  15. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

    2017 · 763 citations
  16. Programmed death ligand-1 expression in non-small cell lung cancer

    2013 · 755 citations
  17. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

    2020 · 753 citations
  18. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex.

    1995 · 735 citations
  19. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

    2017 · 709 citations
  20. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

    2019 · 679 citations
  21. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes

    2019 · 667 citations
  22. A proposal for validation of antibodies

    2016 · 621 citations
  23. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

    2019 · 607 citations
  24. Antibody validation

    2010 · 589 citations
  25. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

    2015 · 534 citations

← Return to the university profile